Continuous glucose monitoring after islet transplantation in type 1 diabetes: an excellent graft function (β-score greater than 7) Is required to abrogate hyperglycemia, whereas a minimal function is necessary to suppress severe hypoglycemia (β-score greater than 3).

ABSTRACT:

Context

For the last 10 yr, continuous glucose monitoring (CGM) has brought up new insights into the accuracy of blood glucose analysis.

Objective

Our objective was to determine how islet graft function was able to influence the various components of dysglycemia after islet transplantation (IT).

Design and setting

We conducted a single-arm open-labeled study with a 3-yr follow-up in a referral center (ClinicalTrial.gov identifiers NCT00446264 and NCT01123187).

Patients

Twenty-three consecutive patients with type 1 diabetes (14 islet alone, nine islet after kidney) received IT within 3 months using the Edmonton protocol.

Intervention

INTERVENTION included 72-h CGM before and 3, 6, 9, 12, 24, and 36 months after transplantation.

Main outcome measure

SUBMITTER: Vantyghem MC 

PROVIDER: S-EPMC3485599 | biostudies-literature | 2012 Nov

REPOSITORIES: biostudies-literature